An Extracellular Vesicle Protein‐Based Machine Learning Framework for Early Detection of Oesophageal Squamous Cell Carcinoma: A Multicentre, Prospective Study
Journal of Extracellular Vesicles · 2026
DOI: 10.1002/jev2.70246 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Journal of Extracellular Vesicles, 2026. Verfasst von Yu Wang und 23 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guan…. Hauptthemen laut MEDLINE: Machine Learning, Early Detection of Cancer, Esophageal Squamous Cell Carcinoma, Extracellular Vesicles. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Key Research and Development Program of China, Enterprises Joint Fund-Key Program of Guangdong Province, Postdoctoral Fellowship Program of China Postdoctoral Science Foundation.
Abstract (Originalsprache)
Early detection of oesophageal squamous cell carcinoma (ESCC) is critical for improving survival, yet current screening is hampered by the lack of effective, non‐invasive methods. Here, we developed and prospectively validated an extracellular vesicle (EV) protein‐based blood test for the preclinical detection of ESCC. We first engineered BarFlare, a high‐sensitivity platform for serum EV protein analysis, and identified a novel biomarker panel that includes EV‐associated squamous cell carcinoma antigen (SCC) and matrix metalloproteinase‐13 (MMP13). These biomarkers were integrated with clinical factors into an interpretable multi‐criteria decision‐making classification fusion (MCF) machine‐learning framework. The MCF model was trained and validated in prospective, multicentre diagnostic cohorts ( n = 1018), and its preclinical detection capability was assessed in a prospective, population‐based longitudinal cohort. The MCF framework accurately distinguished patients with ESCC from healthy controls in a test set (AUC, 0.987) and two external validation cohorts (AUCs, 0.926 and 0.960), including those with early‐stage disease (AUCs, 0.901–0.980). Critically, in the longitudinal cohort, the framework identified individuals who would later develop ESCC from their baseline blood samples with a median lead time of 34.9 months (range, 0.4–72.5) before clinical diagnosis (AUC, 0.864; sensitivity, 73.3%; specificity, 82.2%). The risk score of the model correlated with time to diagnosis, and its dynamic increase significantly outperformed that of traditional serum SCC for preclinical risk stratification. Our validated, blood‐based EV protein signature not only accurately detects prevalent ESCC but also identifies high‐risk individuals years before clinical presentation, providing a powerful, non‐invasive tool that supports risk‐stratified screening and creates a critical window for early, potentially curative intervention. Trial Registration : Chinese Clinical Trial Registry identifiers: ChiCTR2200066733 and ChiCTR2200065610
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, China.
- Department of Clinical Laboratory, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, China.
- Department of Clinical Laboratory, The Affiliated Cancer Hospital of Zhengzhou University & Henan Cancer Hospital, Zhengzhou, China.
- Centre for Disease Control and Prevention of Liwan District of Guangzhou, Guangzhou, China.
- Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, China.
- Department of Clinical Laboratory Medicine, Cancer Hospital of Shantou University Medical College, Shantou, China.
ORCID-Profile: Yu Wang, Wan-Li Liu, Mu-Sheng Zeng, Qian Zhong
Förderung
- National Key Research and Development Program of China
- Enterprises Joint Fund-Key Program of Guangdong Province
- Postdoctoral Fellowship Program of China Postdoctoral Science Foundation
Zitieren
APA
Wang, Y., Xing, S., Wu, Y. X., Xue, N., Chen, P. M., Jin, R. X., Xu, Y. W., Ji, M. F., Peng, Y. H., Liu, Y. T., Chen, L. N., Wu, M., Jiang, Z. Y., Xie, S. H., Luo, Y. L., Zhang, B., Ou, X. Y., Huang, Q., Tian, B. Y., …, & Zhong, Q. (2026). An Extracellular Vesicle Protein‐Based Machine Learning Framework for Early Detection of Oesophageal Squamous Cell Carcinoma: A Multicentre, Prospective Study. Journal of Extracellular Vesicles. https://doi.org/10.1002/jev2.70246
Vancouver
Wang Y, Xing S, Wu YX, Xue N, Chen PM, Jin RX, et al. An Extracellular Vesicle Protein‐Based Machine Learning Framework for Early Detection of Oesophageal Squamous Cell Carcinoma: A Multicentre, Prospective Study. Journal of Extracellular Vesicles. 2026. doi:10.1002/jev2.70246
BibTeX
@article{Wang2026,
author = {Wang, Yu and Xing, Shan and Wu, Ya-Xian and Xue, Ning and Chen, Pei-Min and Jin, Run-Xian and Xu, Yi-Wei and Ji, Ming-Fang and Peng, Yu-Hui and Liu, Yuan-Tao and Chen, Li-Na and Wu, Meng and Jiang, Zi-Ying and Xie, Shang-Hang and Luo, Yi-Ling and Zhang, Biao and Ou, Xin-Yuan and Huang, Qi and Tian, Bo-Yu and Ling, Li and Cao, Su-Mei and Liu, Wan-Li and Zeng, Mu-Sheng and Zhong, Qian},
title = {An Extracellular Vesicle Protein‐Based Machine Learning Framework for Early Detection of Oesophageal Squamous Cell Carcinoma: A Multicentre, Prospective Study},
journal = {Journal of Extracellular Vesicles},
year = {2026},
doi = {10.1002/jev2.70246}
}
EUVIMED